Fonseca Biosciences secures exclusive US rights to XTORO® (finafloxacin otic suspension) 0.3 percent to treat ‘swimmer’s ear’
XTORO is a new chemical entity that is FDA approved for the treatment of acute otitis externa, commonly known as “swimmer’s ear,” caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus LONG BEACH TOWNSHIP, N.J. — (BUSINESS WIRE) — Fonseca Biosciences